@entity6542 ( @entity6542 ) can in some cases influence the course of @entity32 ( @entity1712 and ECP concentration in peripheral tissue). This study was set up to evaluate the efficacy of three-year pre-seasonal @entity6542 with grass pollen allergoid. We measured NALf @entity1712 and ECP concentration both in NALf and blood serum after subsequent SITs. Twenty seven @entity1 aged 26.7 +/- 7.4 (range 18-45) entered this study. They were randomly assigned to treatment with either Pollinex or Allergovit. We observed a progressive fall in NALf @entity1712 in subsequent years: 24.1 +/- 2.4%; 20.2 +/- 4.6%; 9.8 +/- 1.9% vs. 30.4 +/- 3.0% before treatment (p < 0.05, p < 0.05 and p < 0.001, respectively). Also ECP concentration fell after second and third @entity6542 to 15.6 +/- 1.5 ng/ml i 12.96 +/- 1.75 ng/ml vs 23.3 +/- 3.7 ng/ml before @entity6542 (p < 0.05). A significant drop in serum ECP concentration was recorded only after the third @entity7383 .5 +/- 1.23 micrograms/ml vs 5.8 +/- 1.3 micrograms/ml before treatment, p < 0.01. NALf @entity1712 correlated positively with NALf ECP concentration--R2 = 0.92, p < 0.05. Hence, @entity6542 ameliorates @entity32 decreasing significantly activity of eosinophils in nasal mucosa measured as NALf @entity1712 and ECP concentration. This effect seems to be time-depended.

[The influence of a three-year preseasonal specific immunotherapy on selected parameters of XXXX in pollinosis @entity1 ].

@entity6542 :: ('MESH:C562465', 'Disease') :: ['Specific immunotherapy', 'SIT'] @entity32 :: ('MESH:D007249', 'Disease') :: ['allergic inflammation'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia'] @entity7383 :: ('MESH:D016574', 'Disease') :: ['SIT season--2']
@entity32 :: (MESH:D007249,Disease) :: ['allergic inflammation']
